N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology

Krzysztof Marek Mrozik, Orest William Blaschuk, Chee Man Cheong, Andrew Zannettino, Kate Vandyke

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

In many types of solid tumours, the aberrant expression of the cell adhesion molecule N-cadherin is a hallmark of epithelial-to-mesenchymal transition, resulting in the acquisition of an aggressive tumour phenotype. This transition endows tumour cells with the capacity to escape from the confines of the primary tumour and metastasise to secondary sites. In this review, we will discuss how N-cadherin actively promotes the metastatic behaviour of tumour cells, including its involvement in critical signalling pathways which mediate these events. In addition, we will explore the emerging role of N-cadherin in haematological malignancies, including bone marrow homing and microenvironmental protection to anti-cancer agents. Finally, we will discuss the evidence that N-cadherin may be a viable therapeutic target to inhibit cancer metastasis and increase tumour cell sensitivity to existing anti-cancer therapies.

LanguageEnglish
Article number939
JournalBMC cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • Cancer
  • Haematological malignancies
  • Metastasis
  • N-cadherin
  • Therapeutic target

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

@article{cc2362b1cb66438b9f28edaf5c78f62a,
title = "N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology",
abstract = "In many types of solid tumours, the aberrant expression of the cell adhesion molecule N-cadherin is a hallmark of epithelial-to-mesenchymal transition, resulting in the acquisition of an aggressive tumour phenotype. This transition endows tumour cells with the capacity to escape from the confines of the primary tumour and metastasise to secondary sites. In this review, we will discuss how N-cadherin actively promotes the metastatic behaviour of tumour cells, including its involvement in critical signalling pathways which mediate these events. In addition, we will explore the emerging role of N-cadherin in haematological malignancies, including bone marrow homing and microenvironmental protection to anti-cancer agents. Finally, we will discuss the evidence that N-cadherin may be a viable therapeutic target to inhibit cancer metastasis and increase tumour cell sensitivity to existing anti-cancer therapies.",
keywords = "Cancer, Haematological malignancies, Metastasis, N-cadherin, Therapeutic target",
author = "Mrozik, {Krzysztof Marek} and Blaschuk, {Orest William} and Cheong, {Chee Man} and Andrew Zannettino and Kate Vandyke",
year = "2018",
month = "10",
day = "1",
doi = "10.1186/s12885-018-4845-0",
language = "English",
volume = "18",
journal = "BMC cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology. / Mrozik, Krzysztof Marek; Blaschuk, Orest William; Cheong, Chee Man; Zannettino, Andrew; Vandyke, Kate.

In: BMC cancer, Vol. 18, No. 1, 939, 01.10.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology

AU - Mrozik, Krzysztof Marek

AU - Blaschuk, Orest William

AU - Cheong, Chee Man

AU - Zannettino, Andrew

AU - Vandyke, Kate

PY - 2018/10/1

Y1 - 2018/10/1

N2 - In many types of solid tumours, the aberrant expression of the cell adhesion molecule N-cadherin is a hallmark of epithelial-to-mesenchymal transition, resulting in the acquisition of an aggressive tumour phenotype. This transition endows tumour cells with the capacity to escape from the confines of the primary tumour and metastasise to secondary sites. In this review, we will discuss how N-cadherin actively promotes the metastatic behaviour of tumour cells, including its involvement in critical signalling pathways which mediate these events. In addition, we will explore the emerging role of N-cadherin in haematological malignancies, including bone marrow homing and microenvironmental protection to anti-cancer agents. Finally, we will discuss the evidence that N-cadherin may be a viable therapeutic target to inhibit cancer metastasis and increase tumour cell sensitivity to existing anti-cancer therapies.

AB - In many types of solid tumours, the aberrant expression of the cell adhesion molecule N-cadherin is a hallmark of epithelial-to-mesenchymal transition, resulting in the acquisition of an aggressive tumour phenotype. This transition endows tumour cells with the capacity to escape from the confines of the primary tumour and metastasise to secondary sites. In this review, we will discuss how N-cadherin actively promotes the metastatic behaviour of tumour cells, including its involvement in critical signalling pathways which mediate these events. In addition, we will explore the emerging role of N-cadherin in haematological malignancies, including bone marrow homing and microenvironmental protection to anti-cancer agents. Finally, we will discuss the evidence that N-cadherin may be a viable therapeutic target to inhibit cancer metastasis and increase tumour cell sensitivity to existing anti-cancer therapies.

KW - Cancer

KW - Haematological malignancies

KW - Metastasis

KW - N-cadherin

KW - Therapeutic target

UR - http://www.scopus.com/inward/record.url?scp=85054215251&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4845-0

DO - 10.1186/s12885-018-4845-0

M3 - Review article

VL - 18

JO - BMC cancer

T2 - BMC cancer

JF - BMC cancer

SN - 1471-2407

IS - 1

M1 - 939

ER -